Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1972 1
1983 1
1988 2
1989 2
1990 4
1991 3
1992 4
1993 5
1994 2
1995 1
1997 3
1998 2
1999 1
2000 3
2001 2
2004 1
2005 1
2006 1
2007 4
2008 1
2009 2
2010 3
2011 3
2013 1
2015 3
2016 2
2017 1
2018 1
2019 2
2020 4
2021 2
2022 6
2023 8
2024 7
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for m eisei
Your search for M Eisaei retrieved no results
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. de Langen AJ, et al. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. Lancet. 2023. PMID: 36764316 Clinical Trial.
We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m(2) once every 3 weeks) in an open-label manner using interactive response technology. ...
We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m(2) once every 3 weeks) in …
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Wermke M, et al. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9. Nat Med. 2025. PMID: 40205198 Free PMC article. Clinical Trial.
Adhesion Prevention in Gynecologic Surgery: Guidance and Clinical Experience.
Alkatout I, De Wilde RL, Herrmann J, Klapdor R, Meinhold-Heerlein I, Mészáros J, Mustea A, Oppelt P, Pape JM, Schäfer SD, Wallwiener M, Krämer B. Alkatout I, et al. J Clin Med. 2024 Dec 10;13(24):7517. doi: 10.3390/jcm13247517. J Clin Med. 2024. PMID: 39768440 Free PMC article. Review.
[How accurate are self-reported anthropometrics among the Japanese? A scoping review].
Aoyama T, Yuan X, Matsumoto M, Okada E, Okada C, Takimoto H. Aoyama T, et al. Nihon Koshu Eisei Zasshi. 2023 Dec 21;70(12):817-827. doi: 10.11236/jph.23-020. Epub 2023 Sep 5. Nihon Koshu Eisei Zasshi. 2023. PMID: 37673596 Free article. Japanese.
However, it is known that using self-reported height and weight may underestimate the prevalence of obesity (BMI25 kg/m(2)), while its accuracy for underweight (BMI<18.5 kg/m(2)) prevalence is not well-understood. ...Four studies in adults showed that 14.2-37.6% …
However, it is known that using self-reported height and weight may underestimate the prevalence of obesity (BMI25 kg/m(2)), while it …
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
91 results